Moderate to severe, active RA in adults when the response to DMARDs including methotrexate has been inadequate; severe, active & progressive RA in adults not previously treated w/ methotrexate. Reduces the progression rate of joint damage in combination w/ methotrexate. Monotherapy in case of intolerance to methotrexate or when continued treatment w/ methotrexate is inappropriate. In combination w/ methotrexate for active polyarticular juvenile idiopathic arthritis, in patients from 2 yr who have had an inadequate response to ≥1 DMARDs. Active enthesitis-related arthritis in ≥6 yr who have had an inadequate response to, or who are intolerant of, conventional therapy. Severe active ankylosing spondylitis (AS) in adults who have had an inadequate response to conventional therapy; & severe axial spondyloarthritis w/o radiographic evidence of AS but w/ objective signs of inflammation in adults who have had an inadequate response to, or are intolerant to conventional therapy or NSAIDs. Active & progressive psoriatic arthritis in adults when response to previous DMARD therapy has been inadequate; reduce rate of progression of peripheral joint damage in patients w/ polyarticular symmetrical subtypes of the disease & improves physical function. Moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. Severe chronic plaque psoriasis in childn & adolescents from 4 yr who have had an inadequate response to or are inappropriate candidates for topical therapy & phototherapies. Active moderate to severe hidradenitis suppurativa (acne inversa) in adults w/ an inadequate response to conventional systemic HS therapy. Moderate to severe active Crohn's disease, in adults who have not responded despite a full and adequate course of therapy w/ a corticosteroid &/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. Moderate to severe active Crohn's disease in ped patients from 6 yr who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid & an immunomodulator, or who are intolerant to or have contraindications for such therapies. Moderate to severe active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids & 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Non-infectious intermediate, posterior & panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.
Manage Account
Change Password
Sign Out
